WallStreetZenWallStreetZen

NASDAQ: ERAS
Erasca Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ERAS

Based on 9 analysts offering 12 month price targets for Erasca Inc

Min Forecast
$4.00-72.73%
Avg Forecast
$15.11+3.01%
Max Forecast
$25.00+70.42%

Should I buy or sell ERAS stock?

Based on 9 analysts offering ratings for Erasca Inc.

Strong Buy
Strong Buy
6 analysts 66.67%
Buy
3 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ERAS's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ERAS as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their ERAS stock forecasts and price targets.

ERAS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-18
lockedlocked$00.00+00.00%2026-03-16Find Out Why
lockedlocked$00.00+00.00%2026-03-13Find Out Why
lockedlocked$00.00+00.00%2026-03-13
lockedlocked$00.00+00.00%2026-03-13
Clear Street
Top 26%
75
Strong BuyMaintains$20.00+36.33%2026-03-06Find out why
Mizuho
Top 6%
95
BuyMaintains$5.00-65.92%2025-12-09
Guggenheim
Top 17%
84
Strong BuyMaintains$5.00-65.92%2025-11-14
Stifel Nicolaus
Top 14%
87
Strong BuyInitiates Coverage On$4.00-72.73%2025-10-16

1 of 1

Forecast return on equity

Is ERAS forecast to generate an efficient return?

Company
-77.8%
Industry
68.5%
Market
178.91%
ERAS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ERAS forecast to generate an efficient return on assets?

Company
-63.86%
Industry
31.48%
ERAS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ERAS earnings per share forecast

What is ERAS's earnings per share in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
-$0.48
Avg 2 year Forecast
-$0.54
Avg 3 year Forecast
-$0.51

ERAS revenue forecast

What is ERAS's revenue in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$382.5k
Avg 3 year Forecast
$2.8M

ERAS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ERAS$14.67$15.11+3.01%Strong Buy
FOLD$14.41$14.67+1.78%Hold
TERN$50.00$53.75+7.50%Strong Buy
CRSP$46.43$74.27+59.97%Buy
XENE$53.38$72.44+35.71%Strong Buy
View Top Biotech Stocks

Erasca Stock Forecast FAQ

Is Erasca Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 9 Wall Street analysts covering (NASDAQ: ERAS) stock is to Strong Buy ERAS stock.

Out of 9 analysts, 6 (66.67%) are recommending ERAS as a Strong Buy, 3 (33.33%) are recommending ERAS as a Buy, 0 (0%) are recommending ERAS as a Hold, 0 (0%) are recommending ERAS as a Sell, and 0 (0%) are recommending ERAS as a Strong Sell.

If you're new to stock investing, here's how to buy Erasca stock.

What is ERAS's earnings growth forecast for 2026-2028?

(NASDAQ: ERAS) Erasca's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.88%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.77%.

Erasca's earnings in 2026 is -$124,546,000.On average, 12 Wall Street analysts forecast ERAS's earnings for 2026 to be -$147,723,025, with the lowest ERAS earnings forecast at -$176,658,463, and the highest ERAS earnings forecast at -$140,325,995. On average, 10 Wall Street analysts forecast ERAS's earnings for 2027 to be -$167,614,196, with the lowest ERAS earnings forecast at -$213,208,489, and the highest ERAS earnings forecast at -$133,799,205.

In 2028, ERAS is forecast to generate -$157,730,770 in earnings, with the lowest earnings forecast at -$216,254,325 and the highest earnings forecast at -$84,848,276.

What is ERAS's revenue growth forecast for 2026-2028?

(NASDAQ: ERAS) Erasca's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.26%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.29%.

Erasca's revenue in 2026 is $0.On average, 11 Wall Street analysts forecast ERAS's revenue for 2026 to be $0, with the lowest ERAS revenue forecast at $0, and the highest ERAS revenue forecast at $0. On average, 10 Wall Street analysts forecast ERAS's revenue for 2027 to be $118,880,827, with the lowest ERAS revenue forecast at $0, and the highest ERAS revenue forecast at $979,018,573.

In 2028, ERAS is forecast to generate $871,792,729 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $3,589,734,768.

What is ERAS's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ERAS) forecast ROA is -63.86%, which is lower than the forecast US Biotechnology industry average of 31.48%.

What is ERAS's Price Target?

According to 9 Wall Street analysts that have issued a 1 year ERAS price target, the average ERAS price target is $15.11, with the highest ERAS stock price forecast at $25.00 and the lowest ERAS stock price forecast at $4.00.

On average, Wall Street analysts predict that Erasca's share price could reach $15.11 by Mar 18, 2027. The average Erasca stock price prediction forecasts a potential upside of 3.01% from the current ERAS share price of $14.67.

What is ERAS's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ERAS) Erasca's current Earnings Per Share (EPS) is -$0.44. On average, analysts forecast that ERAS's EPS will be -$0.48 for 2026, with the lowest EPS forecast at -$0.57, and the highest EPS forecast at -$0.45. On average, analysts forecast that ERAS's EPS will be -$0.54 for 2027, with the lowest EPS forecast at -$0.69, and the highest EPS forecast at -$0.43. In 2028, ERAS's EPS is forecast to hit -$0.51 (min: -$0.70, max: -$0.27).

What is ERAS's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ERAS) forecast ROE is -77.8%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.